Company: DVAX
Filing Date: 2025-05-06
Form Type: DFAN14A
Source: 0001193125-25-113502
Chunk: 3

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-05-06
Form: DFAN14A
Chunk 3
---
 the record date for the 2025 Annual Meeting as
reported in DVAX’s Definitive Proxy Statement filed with the SEC on April 17, 2025. Each of the Deep Track Parties may be deemed to have the shared power to vote or direct the vote of (and the shared power to dispose or direct the
disposition of) all of the Deep Track Shares. As of the date hereof, none of the other Participants beneficially own any shares of Common Stock.

IMPORTANT INFORMATION AND WHERE TO FIND IT

DEEP TRACK STRONGLY ADVISES ALL STOCKHOLDERS OF DVAX TO READ THE DEFINITIVE PROXY STATEMENT, ANY AMENDMENTS OR SUPPLEMENTS TO SUCH PROXY STATEMENT, AND OTHER
PROXY MATERIALS FILED BY DEEP TRACK WITH THE SEC BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. SUCH PROXY MATERIALS WILL BE AVAILABLE AT NO CHARGE ON THE SEC’S WEBSITE AT WWW.SEC.GOV. THE DEFINITIVE PROXY STATEMENT, WHEN FILED, AND OTHER
RELEVANT DOCUMENTS, WILL ALSO BE AVAILABLE BY DIRECTING A REQUEST TO THE PARTICIPANTS’ PROXY SOLICITOR, INNISFREE M&A INCORPORATED, 501 MADISON AVENUE, 20th FLOOR, NEW YORK, NY 10022 (STOCKHOLDERS CAN CALL TOLL-FREE: (877)-687-1865).

Contacts

Investor Contact

Innisfree M&A Incorporated

Scott Winter / Gabrielle Wolf

+1
212-750-5833

Media Contact

Longacre Square Partners

Item 2: On May 6, 2025, Deep Track posted the following investor presentation to the Website. From time
to time, Deep Track and the other Participants may refer stockholders of the Company to such materials.

Quote from 2024 JP Morgan Healthcare Conference (emphasis added) Unknown Analyst Thank you. And then finally from my end, I’m wondering about your capital allocation strategy. What are your priorities there? Kelly MacDonald Dynavax Technologies Corporation – Senior VP & CFO Take that. So, first and foremost, continuing to drive growth and maximize our commercial brand HEPLISAV-Bwill continue to be an extremely high priority for us, of course, continue to advance our clinical pipeline also remains a priority. And then thirdly, one of the things that Ryan highlighted in the presentation and prepared remarks is really around the way we think about accelerating and deploying that capital through M